A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer

Breast Cancer Research and Treatment

Volumn 45, Issue 3, 1997, Pages 251-262

  Gershanovich, Michael ^a   Garin, August ^b   Baltina, Dace ^c   Kurvet, Ants ^d   Kangas, Lauri ^e   Ellmén, Juha ^e   Archipov, A ^a   Blinov, N ^a   Dzembak, T ^a   Emzins, D ^c   Gorbunova, V ^b   Kondratjev, V ^a   Konstantinova, M ^a   Kutner R ^a   Lichinitser, M ^b   Moiseyenko, V ^a   Nadezidina, T ^b   Nuke, I ^c   Olina, A ^c   Olina, D ^c   Perevodchikova, N ^b   Smirnova, N ^b   Tjulandin, S ^b   Trishkina, E ^a   Tsyrlina, E ^a   Zharkov, S ^b   more..

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^c Sci Inst of Clin and Exp Med   (Latvia)

^d Estonian Cancer Center   (Estonia)

^e ORION CORPORATION   (Finland)

Author keywords

Advanced breast cancer; Antiestrogens; Endocrine therapy; Postmenopausal; Tamoxifen; Toremifene

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; TAMOXIFEN; TOREMIFENE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASTHENIA; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FEMALE; HEADACHE; HEART DISEASE; HORMONAL THERAPY; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PAIN; POSTMENOPAUSE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SWEATING; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINA DISCHARGE; VERTIGO; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; QUALITY OF LIFE; TAMOXIFEN; TOREMIFENE;

EID: 9844266794     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005891506092     Document Type: Article

References (53)

1. Osborne CK: Receptors. In: Harris J, Hellman S, Henderson I et al. (eds) Breast Diseases. Philadelphia, JB Lippincott, 301-325, 1991
2. Early breast cancer trialists collaborative group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 71-85, 1992
3. Goldhirsch A, Wood WC, Senn H-J, Glick JH, Gelber RD: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87: 1441-1445, 1995
4. Love RR: Prospects for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst 82: 18-22, 1990
5. Powles TJ, Hardy JK, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Sinnet HD, Tillyer CR, Treleaven JG: A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for preventing breast cancer. Br J Cancer 60: 126-131, 1990
6. Kangas L, Kallio S, Blanco G, Grönroos M, Kallio S, Kar jalainen A, Perilä M, Södervall M, Toivola R: A new triphenylethylene compound. FC-1157a. II. Antitumor effects. Cancer Chemother Pharmacol 17: 109-114, 1986
7. Kangas L: Agonistic and antagonistic effects of antiestrogens in different target organs. Acta Oncol 31: 143-146, 1992
8. Jordan VC, Dix CJ, Naylor KE, Prestwitch G, Rowsby L: Nonsteroidal antiestrogens: their biological effects and potential mechanism of action. J Toxicol Environ Health 4: 363-390, 1978
9. Wärri AM, Huovinen RL, Laine AM, Martikainen PM, Härkönen PL: Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 85: 1412-1418, 1993
10. Lahti EI, Knip M, Laatikainen TJ: Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen. Cancer 74: 618-624, 1994
11. Rankumar T, Adler S: Differential positive and negative transcriptional regulation by tamoxifen. Endocrinol 136: 536-542, 1995
12. Wiseman H: Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances. TIPS 15: 83-89, 1994
13. Su H-D, Mazzei GJ, Vogler WR, Kuo JF: Effect of tamoxifen, a nonsteroidal antiestrogen, on phospholipid/calcium- dependent protein kinase and phosphorylation of its endogenous substrate proteins from the rat brain and ovary. Biochem Pharmacol 34: 3649-3653, 1985
14. Valverde MA, Mintenig GM, Sepúlveda FV: Differential effects of tamoxifen and I- on three distinguishable chloride currents activated in T84 intestinal cells. Eur J Physiol 425: 552-554, 1993
15. DeGregorio M, Ford JM, Benz CC, Wiebe VJ: Toremifene: Pharmacological and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol 7: 1359-1364, 1989
16. 1 acid glycoprotein. Eur J Cancer 26: 432-436, 1990
17. Ahotupa M, Hirsimäki P, Hirsimäki P, Pärssinen R, Mäntylä E: Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen-induced hepatocarcinogenesis in the rat. Carcinogenesis 15: 863-868, 1994
18. Thangaraju M, Ezhilarasi R, Sachdanandam P: Effect of tamoxifen on erythrocyte membrane lipids, lipid peroxides, and antioxidative enzymes in breast cancer women. Cancer Biochem Biophys 14: 297-302, 1995
19. Kendall ME, Rose DP: The effects of diethylstilbesterol, tamoxifen, and toremifene on estrogen-inducible hepatic proteins and estrogen receptor proteins in female rats. Toxicol Appl Pharmacol 114: 127-131, 1992
20. Számel I, Hindy I, Vincze B, Eckhardt S, Kangas L, Hajba A: Influence of toremifene on the endocrine regulation in breast cancer patients. Eur J Cancer 30A: 154-158, 1994
21. Robinson SP, Jordan VC: Antiestrogenic action of toremi fene on hormone-dependent, -independent, and heterogenous breast tumor growth in the athymic mouse. Cancer Res 49: 1758-1762, 1989
22. Moon RC, Steele VE, Kelloff GJ, Thomas CF, Detrisac CJ, Mehta RG, Lubet RA: Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone. Anticancer Res 14: 889-894, 1994
23. Hietanen T, Baltina D, Johansson R et al.: High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer - An ongoing phase II multicenter Finnish-Latvian cooperative study. Breast Cancer Res Treat 16: S37-40, 1990
24. Valavaara R, Pyrhönen S, Heikkinen M, Rissanen P, Blanco G, Thölix E, Nordman E, Taskinen P, Holsti L, Hajba A: Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase 11 study. Eur J Cancer Clin Oncol 24: 785-790, 1988
25. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
26. Oyen MM, Greech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of Eastern Cooperative Oncology Group. Am J Oncol 5: 649-655, 1982
27. WHO Adverse Reaction Dictionary. WHO Collaborating Center for International Drug Monitoring, Uppsala, Sweden. March, 1988
28. Henderson IC. Endocrine therapy of metastatic breast cancer. In: Harris JR, Hellman S, Henderson IC et al. (eds) Breast Diseases. Philadelphia, PA, Lippincott, 559-603, 1991
29. Henderson IC: Chemotherapy for metastatic breast cancer. In: Harris JR, Hellman S, Henderson IC et al. (eds) Breast Diseases. Philadelphia, JB, Lippincott, 604-665, 1991
30. Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I, Schoenfelder J: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13: 2556-2566, 1995
31. Bratherton DG, Brown CH, Buchanan R, Hall V, Kingsley Pillers EM, Wheeler TK, Williams CJ: A comparison of two doses of tamoxifen (Nolvadex*) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer 50: 199-205, 1984
32. Lipton A, Harvey HA, Hamilton RW: Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 62: 887-889, 1984
33. Fisher B, Constantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov N, Wolmark N, Wickerham D, Fisher E, Margolese R, Robidoux A, Shibata H, Terz J, Paterson A, Feldman H, Farrar W, Evans J, Lickley H, Ketner M: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320: 479- 484, 1989
34. Kaiser-Kupfer MI, Lippman ME: Tamoxifen retinopathy. Cancer Treat Rep 62: 315-320, 1978
35. Beck M, Mills PU: Ococar assessment of patients treated with tamoxifen. Cancer Treat Rep 63: 1833-1834, 1979
36. Bishop J, Murray R, Webster L, Pitt P, Stokes K, Fennessy A, Olver I, Leber G: Phase I clinical and pharmacokinetic study of high-dose toremifene in postmenopausal patients with advanced breast cancer. Cancer Chemother Pharmacol 30: 174-178, 1992
37. Fornander T, Cedermark B, Mattsson A, Skoog L, Theve T, Askergren J, Rutqvist L, Glas U, Silversward C, Somell A, Wilking N, Hjalmar M: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1: 117- 120, 1989
38. Fisher B, Constantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, other NSABP contributors: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86: 527- 537, 1994
39. van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney LALM, Gimbrère CHF, Otter R, Schouten LJ, Damhuis RAM, Bontenbal M, Diepenhorst FW, van den Belt-Dusebout SW, van Tintere H: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343: 448-452, 1994
40. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T: Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53: 3919-3924, 1993
41. Hirsimäki P, Hirsimäki Y, Nieminen L, Payne BJ: Tamoxifen induces hepatocellular carcinoma in rat liver - a 1-year study with 2 antiestrogens. Arch Toxicol 67: 49-54, 1993
42. Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, Williams GM: Major difference is the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl: CD (BR) rats. Cancer Res 53: 4534-4541, 1993
43. White INH, De Matteis F, Davies A, Smoith LL, Crofton Sleigh C, Venitt S, Hewer A, Philips DH: Genotoxic potential of tamoxifen and analogues in female Fischer F344/N rats, DBA/2 and C57B1/6 mice and in human MCL-5 cells. Carcinogenesis 13: 2197-2203, 1992
44. Vancutsem PM, Lazarus P, Williams GML: Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer 54: 3864-3867, 1994
45. Carthew P, Martin EA, White INH, De Matteis F, Edwards RE, Dorman BM, Heydon RT, Smith LL: Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital. Cancer Res 55: 544-547, 1995
46. Fornander T, Hellström A-C, Moberger B: Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 85: 1850-1855, 1993
47. Mühlemann K, Cook LS, Weiss NS: The incidence of hepatocellular carcinoma in US white women with breast cancer after introduction of tamoxifen in 1977. Breast Cancer Res Treat 30: 201-204, 1994
48. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87: 645-651, 1995
49. Jordan VC, Morrow M: Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 30A: 1714-1721, 1994
50. Jordan VC: Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol 35: 195-211, 1995
51. Robinson DC, Bloss JD, Schiano MA: A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol Oncol 59: 186-190, 1995
52. Curtis ER, Boice JD, Shiner DA, Hankey BF, Fraumeni JF Jr: Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 88: 832-834, 1996
53. Wilking N, Isaksson E, Schooltz E: Tamoxifen and Secondary Tumours an Update. Drug Safety 16: 104-117, 1997